NCT03569514View on ClinicalTrials.gov

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not yet recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Anthrax
Interventions
DRUG

AIGIV

Anthrax Immune Globulin Intravenous (Human)

Sponsors
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY